Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Cash from Financing Activities: 2019-2021

Historic Cash from Financing Activities for Black Diamond Therapeutics (BDTX) over the last 3 years, with Sep 2021 value amounting to $64,000.

  • Black Diamond Therapeutics' Cash from Financing Activities fell 76.30% to $64,000 in Q3 2021 from the same period last year, while for Sep 2021 it was $1.6 million, marking a year-over-year decrease of 99.54%. This contributed to the annual value of $25.5 million for FY2024, which is 64.48% down from last year.
  • Per Black Diamond Therapeutics' latest filing, its Cash from Financing Activities stood at $64,000 for Q3 2021, which was down 65.22% from $184,000 recorded in Q2 2021.
  • Black Diamond Therapeutics' Cash from Financing Activities' 5-year high stood at $213.8 million during Q1 2020, with a 5-year trough of -$70,000 in Q2 2019.
  • For the 3-year period, Black Diamond Therapeutics' Cash from Financing Activities averaged around $38.2 million, with its median value being $481,000 (2021).
  • Data for Black Diamond Therapeutics' Cash from Financing Activities shows a maximum YoY plummeted of 99.78% (in 2021) over the last 5 years.
  • Black Diamond Therapeutics' Cash from Financing Activities (Quarterly) stood at $83.5 million in 2019, then tumbled by 99.01% to $830,000 in 2020, then crashed by 76.30% to $64,000 in 2021.
  • Its Cash from Financing Activities was $64,000 in Q3 2021, compared to $184,000 in Q2 2021 and $481,000 in Q1 2021.